Drug Trial News

RSS

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States.

3 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

AF patients treated with rivaroxaban for stroke prevention experience low rates of bleeding and stroke

Atrial fibrillation (AF) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, reveals real-world data from the XANTUS study presented at ESC Congress today.

2 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial.

1 Sep 2015

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today.

1 Sep 2015

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

HIV-1 infection with multiple founder variants points to poorer clinical outcomes than infection with a single variant, according to a paper published today in the journal Nature Medicine.

1 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015

Resverlogix Corp. is pleased to announce that Dr. Norman Wong, chief scientific officer of Resverlogix Corp. presented new data at the European Society of Cardiology (ESC) Congress 2015 in a poster presentation titled: "RVX-208, an orally active BET inhibitor, lowers CVD risk by activities beyond raising ApoA-I/HDL."

31 Aug 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Ascletis today announced it received the approval from the Taiwan Food and Drug Administration (TFDA) to start phase II clinical trial for its all-oral interferon (IFN)-free regimen to treat chronic hepatitis C (CHC).

31 Aug 2015

PATHWAY 3 study: Half dose combination of common diuretics reduces blood pressure

The combination of two commonly used diuretics, each at half dose, can significantly reduce blood pressure without the side-effects caused by full doses of either alone, researchers from the PATHWAY 3 study have found.

31 Aug 2015

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.

31 Aug 2015

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Results of a clinical trial seem to show the first effective treatment for the negative symptoms - withdrawal, lack of emotion, and apathy - associated with schizophrenia.

31 Aug 2015

Passport Health participates in clinical study to test effects of oral typhoid vaccination

Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies.

28 Aug 2015

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.

27 Aug 2015

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

26 Aug 2015

Omega-3 supplements fail to slow cognitive decline in older persons, NIH clinical study shows

While some research suggests that a diet high in omega-3 fatty acids can protect brain health, a large clinical trial by researchers at the National Institutes of Health found that omega-3 supplements did not slow cognitive decline in older persons. With 4,000 patients followed over a five-year period, the study is one of the largest and longest of its kind.

26 Aug 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London.

26 Aug 2015

Drug Trial News

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

AF patients treated with rivaroxaban for stroke prevention experience low rates of bleeding and stroke

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

PATHWAY 3 study: Half dose combination of common diuretics reduces blood pressure

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Passport Health participates in clinical study to test effects of oral typhoid vaccination

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Omega-3 supplements fail to slow cognitive decline in older persons, NIH clinical study shows

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News